<bill session="111" type="s" number="2942" updated="2023-01-11T13:16:41Z">
  <state datetime="2010-01-21">REFERRED</state>
  <status>
    <introduced datetime="2010-01-21"/>
  </status>
  <introduced datetime="2010-01-21"/>
  <titles>
    <title type="display">Nanotechnology Safety Act of 2010</title>
    <title type="official" as="introduced">A bill to amend the Federal Food, Drug, and Cosmetic Act to establish a nanotechnology program.</title>
    <title type="short" as="introduced">Nanotechnology Safety Act of 2010</title>
  </titles>
  <sponsor bioguide_id="P000590"/>
  <cosponsors>
    <cosponsor bioguide_id="C000141" joined="2010-01-21"/>
    <cosponsor bioguide_id="F000457" joined="2010-07-27"/>
  </cosponsors>
  <actions>
    <action datetime="2010-01-21">
      <text>Introduced in Senate</text>
    </action>
    <action datetime="2010-01-21">
      <text>Sponsor introductory remarks on measure.</text>
      <reference ref="CR S123-124"/>
    </action>
    <action datetime="2010-01-21" state="REFERRED">
      <text>Read twice and referred to the Committee on Health, Education, Labor, and Pensions.</text>
      <reference ref="CR S124-125" label="text of measure as introduced"/>
    </action>
  </actions>
  <committees>
    <committee code="SSHR" name="Senate Health, Education, Labor, and Pensions" subcommittee="" activity="Referral"/>
  </committees>
  <relatedbills/>
  <subjects>
    <term name="Health"/>
    <term name="Advanced technology and technological innovations"/>
    <term name="Drug safety, medical device, and laboratory regulation"/>
    <term name="Medical research"/>
    <term name="Technology assessment"/>
  </subjects>
  <amendments/>
  <summary date="2010-02-05T17:18:49Z" status="Introduced in Senate">Nanotechnology Safety Act of 2010 - Amends the Federal Food, Drug, and Cosmetic Act to require the Secretary of Health and Human Services (HHS) to establish within the Food and Drug Administration (FDA) a program for the scientific investigation of nanoscale materials included or intended for inclusion in FDA-regulated products to address: (1) the potential toxicology of such materials; (2) the effects of such materials on biological systems; and (3) the interaction of such materials with biological systems.</summary>
</bill>
